GlassScriptPhysician profile
Chukwuemeka Okafor
NPI 1053725713
$1,327.09
in general payments reported to CMS, 2019-2025
12 companies · $190 in 2025
The $190 reported for 2025 was more than what 80% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.08 · 2020: $637 · 2021: $113 · 2022: $52.59 · 2023: $94.57 · 2024: $188 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $495.78 | 2020 | |
| Medtronic, INC. | $379.19 | 2021-2025 | Intellis Adaptivestim, Bis |
| Abbott Laboratories | $234.61 | 2020-2021 | |
| Spr Therapeutics, INC | $52.08 | 2019 | |
| Janssen Pharmaceuticals, INC | $42.89 | 2022-2023 | Xarelto |
| Conmed Corporation | $23.73 | 2024 | Airseal |
| Pfizer INC. | $19.16 | 2023 | |
| Merck Sharp & Dohme LLC | $17.11 | 2023 | Verquvo |
| Baxter Healthcare | $16.31 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $15.82 | 2025 | Exparel |
| Alcon Vision LLC | $15.30 | 2022 | |
| Chiesi USA, INC. | $15.11 | 2023 | Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chukwuemeka Okafor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.